This article looked at the effectiveness of bevacizumab (Avastin) with chemotherapy for metastatic colorectal cancer (mCRC) in a real-world setting. The authors found that the addition of bevacizumab to chemotherapy regimens provides survival benefits in patients who cannot undergo curative local treatment.

This study compared the use of pembrolizumab (Keytruda) to chemotherapy for the treatment of patients with colorectal cancer (CRC) and high microsatellite instability (MI). This study showed that patients who received pembrolizumab had a better outcome than those who were given chemotherapy.

This study investigated the long-term outcomes of patients with colorectal cancer (CRC) and liver metastases (LM; cancer spread to the liver) undergoing the ALPPS (associating liver partition and portal vein ligation) procedure. Researchers suggested that patients with LM that were unfit for surgical removal achieved positive long-term outcomes and reduced mortality with this procedure.

The study evaluated the optimal timing of surgery for colorectal cancer liver metastasis (CRLM) after chemotherapy (CT). The main finding was that surgery within 5 weeks after CT may improve patients' outcomes.

This study investigated the effectiveness of bevacizumab plus chemotherapy and deep electro-hyperthermia (DEH) for advanced colon cancer (CC). Researchers suggested that this treatment improves the outcomes of these patients. 

This study investigated the occurrence of cachexia (CX; weight loss and muscle wasting) in patients with advanced colorectal cancer after first-line therapy. Researchers suggested that CX is present in half of these patients within 24 weeks after starting first-line therapy.

This study compared the effectiveness of FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) with either cetuximab (Erbitux) or bevacizumab (Avastin) in the treatment of advanced colorectal cancer (CRC). Researchers suggested that FOLFIRI with cetuximab resulted in improved response and longer survival for these patients.

This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment.

This trial was carried out to examine the optimal time interval between completing chemoradiotherapy (CRT) and robotic-assisted surgery (RAS) in patients with rectal cancer. The trial found that RAS is safe and effective after 10-12 weeks of CRT.

This study investigated the long-term health-related quality of life (HQL) after colorectal cancer (CRC) surgery. Researchers suggested that overall long-term HQL was good, although some patients may need closer follow-up.